ECTSS Home  |  Past Meetings
Eastern Cardiothoracic Surgical Society

Back to 2022 Abstracts


Intermediate Term Analysis Of A Community Based Lung Cancer Screening Program
Jiatian Qu, Stephanie L. Scarlett, Brian R. Lace, Danielle J. Smith, Stella M. Antimarino, Nicole M. Larson, Allen M. Rakers, Ashton N. Beckman, Chuanxing Qu, Michael F. Szwerc.
Excela Health, Greensburg, PA, USA.

OBJECTIVE: Low Dose CT (LDCT) screening has been shown to significantly reduce lung cancer mortality rates. There has been little research exploring stage at diagnosis and survival. METHODS: Through a retrospective review of a LDCT database, survivability curves based on histology and stage were constructed. A t-test was used to determine ratios of lung cancer diagnosis proportion differences of stages between our data and those of NLST and NELSON. Survival rates as well as Kaplan Meier survival curves were calculated. RESULTS: From January 2016 through April 2022, a total of 14,086 LDCTs were performed in 5329 patients. 183 cancers were diagnosed (3.4% cancer detection rate). When comparing the proportion of cancer stages to NLST, this study found a significantly lower percentage of Stage IV cancers (p = .01552). In addition, this study detected a significantly higher proportion of Stage I cancers (p = 0.0002) and lower proportion of Stage IV cancers (p < 0.00001) in comparison to diagnoses done without LDCT. Survival curves were constructed for each stage of adenocarcinoma and squamous cell carcinoma. CONCLUSIONS: This study detected lower ratios of Stage IV cancers compared to NLST as well as diagnoses done without LDCT screening. There were no significant difference in survival rates between patients diagnosed with squamous cell carcinoma and adenocarcinoma. Future research should continue to follow LDCT patient survivability over longer periods of time with larger patient populations.



Back to 2022 Abstracts